ASHG 2019
Recent articles
Antidote to ‘poison’ DNA may treat lethal form of epilepsy
An experimental drug silences a DNA segment and seems to prevent seizures and death in a condition related to autism.
Antidote to ‘poison’ DNA may treat lethal form of epilepsy
An experimental drug silences a DNA segment and seems to prevent seizures and death in a condition related to autism.
Brain ‘organoids’ point to new drug target for fragile X syndrome
New findings hint at why drugs that work in mouse models of fragile X syndrome have not been effective in people.
Brain ‘organoids’ point to new drug target for fragile X syndrome
New findings hint at why drugs that work in mouse models of fragile X syndrome have not been effective in people.
Massive project doubles list of genes tied to autism
The largest analysis of sequences from autistic people and their families implicates 184 genes in the condition — nearly doubling the previous estimate.
Massive project doubles list of genes tied to autism
The largest analysis of sequences from autistic people and their families implicates 184 genes in the condition — nearly doubling the previous estimate.
Explore more from The Transmitter
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.